Evotec SE
A drug discovery and development partner for pharma, biotech, and academia.
EVT | F
Overview
Corporate Details
- ISIN(s):
- DE0005664809 (+1 more)
- LEI:
- 529900F9KI6OYITO9B12
- Country:
- Germany
- Address:
- Essener Bogen 7, 22419 Hamburg
- Website:
- https://www.evotec.com/en
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Evotec SE is a life science company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies, as well as academic institutions. The company offers a fully integrated research and development value chain, leveraging proprietary technology platforms and deep disease understanding to accelerate the creation of new medicines. Its expertise spans multiple therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics subsidiary, the company also provides advanced solutions for the design, development, and manufacturing of biologics. Evotec operates through flexible partnership models, aiming to enhance the speed, efficiency, and quality of bringing novel treatments to patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-09 10:40 |
Evotec SE: Prof. Dr. Iris Low-Friedrich, buy
|
English | 5.9 KB | ||
| 2025-12-08 07:00 |
Evotec closes sale of Just Evotec Biologics Toulouse site to Sandoz
|
English | 13.3 KB | ||
| 2025-12-04 08:30 |
Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport…
|
English | 14.3 KB | ||
| 2025-12-03 13:28 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.9 KB | ||
| 2025-11-28 11:23 | English | 16.6 KB | |||
| 2025-11-24 10:39 | English | 16.9 KB | |||
| 2025-11-17 15:27 |
Release of a capital market information
|
English | 8.2 KB | ||
| 2025-11-14 16:14 |
Evotec SE: Dr. Cord Dohrmann, sell
|
English | 6.1 KB | ||
| 2025-11-13 13:19 |
Evotec SE: Wesley Wheeler, buy
|
English | 6.0 KB | ||
| 2025-11-12 07:30 |
Evotec receives milestone payment from Bristol Myers Squibb following IND accep…
|
English | 14.5 KB | ||
| 2025-11-06 15:35 |
Release of a capital market information
|
English | 6.2 KB | ||
| 2025-11-06 00:00 |
Q3 statement / Q3 financial report 2025
|
English | 296.9 KB | ||
| 2025-11-05 07:30 |
Evotec SE reports 9M 2025 results: Continued strong execution on strategic prio…
|
English | 19.0 KB | ||
| 2025-11-04 22:05 |
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulti…
|
English | 15.8 KB | ||
| 2025-10-29 09:45 |
Evotec SE to announce results for the first nine months 2025 on 05 November 2025
|
English | 11.5 KB |
Automate Your Workflow. Get a real-time feed of all Evotec SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Evotec SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Evotec SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-06 | Dohrmann, Dr. Cord | Board | Other | None | 91,363.32 EUR |
| 2024-10-01 | Rouxel, Laetitia | Board | Other | None | 58,396.84 EUR |
| 2024-09-13 | Wojczewski, Dr. Christian | Board | Buy | None | 61,087.50 EUR |
| 2024-09-05 | Dalbiez, Aurélie | Board | Buy | None | 21,202.55 EUR |
| 2024-09-02 | Wojczewski, Dr. Christian | Board | Buy | None | 64,466.00 EUR |
| 2024-08-29 | Löw-Friedrich, Prof. Dr. Iris | Supervisory board | Buy | None | 100,050.00 EUR |
| 2024-08-23 | Wojczewski, Dr. Christian | Board | Buy | None | 113,291.94 EUR |
| 2024-08-22 | Johnstone, Dr. Craig | Board | Buy | None | 16,553.03 EUR |
| 2024-08-19 | Wojczewski, Dr. Christian | Board | Buy | None | 59,766.00 EUR |
| 2024-05-03 | Dohrmann, Dr. Cord | Board | Other | None | 76,220.10 EUR |
Peer Companies
